Table 1.
Immunotherapeutic drugs approved by FDA (1997–2019)
| Drug | Description | Mechanism | First FDA approval |
|---|---|---|---|
| Atezolizumab | Humanised Anti-PDL1 | Checkpoint inhibition | 2016 |
| Avelumab | Human anti-PDL1 | Checkpoint inhibition | 2017 |
| Axicabtagene ciloleucel | CAR-T cell anti-CD19 | Neoantigen recognition | 2017 |
| Bevacizumab | Humanised anti-VEGF | Target therapy (anti-angiogenic effect) | 2004 |
| Blinatumomab | Bispecific murine anti-CD19 and anti-CD3 | Neoantigen recognition | 2014 |
| Brentuximab vedotin | Chimeric anti-human CD30 (antibody-drug conjugate) | Neoantigen recognition | 2011 |
| Cemiplimab | Human anti-PD1 | Checkpoint inhibition | 2018 |
| Cetuximab | Chimeric anti-EGFR | Target therapy (tumour anti-proliferative effect) | 2004 |
| Daratumumab | Human anti-CD38 | Neoantigen recognition Immunomodulation |
2015 |
| Denosumab | Humanised anti-RANKL | Immunomodulation (anti-osteoclast activity) | 2010 |
| Dinutuximab | Chimeric anti-GD2 | Neoantigen recognition | 2015 |
| Durvalumab | Human anti-PDL1 | Checkpoint inhibition | 2017 |
| Elotuzumab | Humanised anti-SLAMF7 | Neoantigen recognition | 2015 |
| Gemtuzumab ozogamicin | Humanised anti-CD33 (antibody-drug conjugate) | Neoantigen recognition Target therapy | 2001 |
| Ibritumomab tiuxetan | Murine anti-CD20 type II (radionuclide-linked Ab) | Neoantigen recognition Target therapy | 2002 |
| Inotuzumab ozogamicin | Humanised anti-CD22 (antibody-drug conjugate) | Neoantigen recognition | 2017 |
| Ipilimumab | Human anti-CTLA4 | Checkpoint inhibition | 2011 |
| Necitumumab | Human anti-EGFR | Neoantigen recognition Target therapy (tumour anti-proliferative effect) | 2015 |
| Nivolumab | Human anti-PD1 | Checkpoint inhibition | 2014 |
| Obinutuzumab | Humanised anti-CD20 type II | Neoantigen recognition | 2013 |
| Ofatumumab | Human anti-CD20 type I | Neoantigen recognition | 2010 |
| Panitumumab | Human anti-EGF | Target therapy (tumour anti-proliferative effect) | 2006 |
| Peginterferon alfa-2b | Immune modulator, anti-proliferative and anti-viral | Immunomodulation | 2011 |
| Pembrolizumab | Humanised anti-PD1 | Checkpoint inhibition | 2014 |
| Pertuzumab | Humanised anti-HER2 | Neoantigen recognition | 2012 |
| Polatuzumab vedotin | Humanised anti-CD79b (Ab-drug conjugate) | Neoantigen recognition Target therapy | 2019 |
| Ramucirumab | Human anti-VEGFR-2 | Target therapy (anti-angiogenic effect) | 2014 |
| Rituximab | Chimeric anti-CD20 type I | Neoantigen recognition | 1997 |
| Sipuleucel-t | PAP-specific APC based vaccine | Neoantigen recognition | 2010 |
| Tisagenlecleucel | CAR-T cell anti-CD19 | Neoantigen recognition | 2017 |
| Tositumomab | Radionuclide-linked murine anti-CD20 type II | Neoantigen recognition Target therapy | 2003 |
| Trastuzumab | Humanised anti-HER2 | Neoantigen recognition | 1998 |
| Trastuzumab emtansine | Humanized anti-HER2 (conjugated antibody) | Neoantigen recognition | 2013 |
| Tremelimumab | Human anti-CTLA4 | Checkpoint inhibition | 2015 |
Record of immunotherapeutic drugs approved by the FDA (www.fda.gov) for the treatment of several cancer types and their mechanism of action (data updated until 31/Dec/2019).